SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility

被引:63
作者
Grieve, Richard [1 ]
Grishchenko, Marina [1 ]
Cairns, John [1 ]
机构
[1] London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England
关键词
Cost-utility; EQ-5D; SF-6D; Health utilities; CHRONIC HEPATITIS-C; PLUS RIBAVIRIN; HEALTH; PEGINTERFERON; EUROQOL; THERAPY;
D O I
10.1007/s10198-008-0097-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
The choice of instrument (e.g. EQ-5D vs. SF-6D) can lead to different health-related utility scores, but it is unclear why these differences arise and whether they change cost utility analysis (CUA) results. This paper addresses these issues using a case study where using SF-6D rather EQ-5D led to greater utility gain and a lower cost per QALY for treatment. The paper examines reasons for this difference. This paper finds that an important factor was the inclusion in the SF-6D descriptive system of separate items for "vitality" and "social functioning", not explicitly included in EQ-5D. Further studies are required that examine the impact of the choice of instrument on cost-utility.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 25 条
  • [1] [Anonymous], GUID METH TECHN APPR
  • [2] Comparing utility scores before and after hearing-aid provision: Results according to the EQ-5D, HUI3 and SF-6D
    Barton G.R.
    Bankart J.
    Davis A.C.
    Summerfield Q.A.
    [J]. Applied Health Economics and Health Policy, 2004, 3 (2) : 103 - 105
  • [3] Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population
    Bharmal, Murtuza
    Thomas, Joseph, III
    [J]. VALUE IN HEALTH, 2006, 9 (04) : 262 - 271
  • [4] How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?
    Boonen, Annelies
    van der Heijde, Desiree
    Landewe, Robert
    van Tubergen, Astrid
    Mielants, Herman
    Dougados, Maxime
    van der Linden, Sjef
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) : 771 - 777
  • [5] The estimation of a preference-based measure of health from the SF-36
    Brazier, J
    Roberts, J
    Deverill, M
    [J]. JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) : 271 - 292
  • [6] A comparison of the EQ-5D and SF-6D across seven patient groups
    Brazier, J
    Roberts, J
    Tsuchiya, A
    Busschbach, J
    [J]. HEALTH ECONOMICS, 2004, 13 (09) : 873 - 884
  • [7] Measuring health-related utility: Why the disparity between EQ-5D and SF-6D?
    Bryan S.
    Longworth L.
    [J]. The European Journal of Health Economics, 2005, 6 (3) : 253 - 260
  • [8] Modeling valuations for EuroQol health states
    Dolan, P
    [J]. MEDICAL CARE, 1997, 35 (11) : 1095 - 1108
  • [9] A comparison of health utility measures for the evaluation of multiple sclerosis treatments
    Fisk, JD
    Brown, MG
    Sketris, IS
    Metz, LM
    Murray, TJ
    Stadnyk, KJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (01) : 58 - 63
  • [10] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982